AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 62 min read$NTRA

Chapman Steven Leonard sold $819K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 3,076 shares of Natera, Inc. (NTRA) at an average of $266.40 ($259.98–$268.22, $0.82M total) across 7 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Aug 6, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the record of insider activity, but the pre-arranged 10b5-1 structure reduces the likelihood of a new fundamental narrative.

02

Market read

Traders may monitor insider activity for sentiment, but this specific filing is unlikely to drive a durable repricing without additional company news.

03

What to watch

The article does not state whether the CEO increased other holdings, sold for tax/option exercises, or whether there were concurrent company-specific catalysts; without that, the trading signal is weak.

Relevance 4/10Novelty 4/10Timing: filed Aug 5, covering sales executed Aug 3

Background

This is an SEC Form 4 insider transaction for Natera, Inc., reported by the CEO and President.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold about $819K of NTRA shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 shows a scheduled 10b5-1 sale (not a surprise discretionary sale) and provides no accompanying operational or guidance change.

Market effects

Sector

Minimal; insider selling in a single biotech/diagnostics name does not reset sector fundamentals.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations, so any negative read-through could be overdone.

Key entities

  • issuer
    Natera, Inc.

    Company whose CEO and President reported an open-market sale of shares on a 10b5-1 plan.

  • insider
    Chapman Steven Leonard

    CEO and President who sold 3,076 shares across seven trades on Aug 3, 2026.

Read at source← All news

Related articles

AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

timothysykes.com6 min
AUG 7
$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

benzinga.com4 min
AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min